Gyroscope secures $148M to develop treatment for rare eye diseases
Longevity Technology - 29-Mar-2021Funds to advance gene therapy for age-related macular degeneration & innovative delivery system
Gyroscope Therapeutics
London-based company developing gene therapies and delivery technologies for eye diseases
Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (AMD). Gyroscope is headquartered in London with locations in Philadelphia and San Francisco.
Acquired by Novartis in Dec 2021.
Visit website: https://www.gyroscopetx.com/
Details last updated 31-Mar-2021
Gyroscope Therapeutics News
Mentioned in this Resource
Other people at Gyroscope Therapeutics
